FDA grants emergency authorisation to another Covid 19 test
BGI's test now has global approvals through US FDA, Europe's CE-IVD, and China's NMPA Kits are currently being distributed to more than 70 countries and regions worldwide. It is highly sensitive, rapid test with 3-hour turnaround time
CAMBRIDGE: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its RT-PCR kit for detecting SARS-CoV-2 to BGI Genomics Co. Ltd. (SZSE:300676) and its US subsidiary BGI Americas Corp.
BGI's highly sensitive test can return results within three hours. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in bronchoalveolar lavage fluid (BALF) and throat swabs.
BGI's RT-PCR kit for detecting SARS-CoV-2
BGI's RT-PCR kit for detecting SARS-CoV-2
"The authorization of our diagnostic test for COVID-19 in the US will provide high-quality, high-volume testing capabilities to the US, and enable medical professionals to respond quickly to diagnose patients, preventing further spread of infection," said Ye Yin, CEO of BGI Genomics.
"As one of the first responders to the outbreak in China, we quickly scaled up our production and have deployed large numbers of kits for testing in China and globally in countries where our test kit has been approved. We are committed in bringing rapid, accurate testing capabilities on a massive scale to bolster detection efforts throughout the United States and globally in order to fight the spread of this disease."
Advantages of BGI's test include:
High sensitivity– Limit of Detection at 100 copies/mL in BALF and 150 copies/mL in throat swabs
High specificity – No cross-reactivity with 54 human respiratory pathogens
Fast TAT – Sample to result in 3 hours
Ease of use – All inclusive with pre-mixed reaction reagents
Easy interpretation – Analysis of one target with well-defined controls
BGI has been on the forefront of testing for SARS-CoV-2. Following the outbreak of the novel coronavirus in China, BGI was among the first few companies to have developed diagnostic tests that received emergency approval from China's National Medical Products Administration (NMPA) on January 26, 2020, followed by CE-IVD marking on March 2, 2020. BGI currently has a daily manufacturing capacity of 600,000 reactions and is actively scaling up to meet rapidly growing global demand. As of March 22, BGI has produced a total of 4.72 million tests. The company has performed over 500,000 SARS-CoV-2 tests in its own central laboratories in China and is distributing its SARS-CoV-2 detection kits to more than 70 countries and regions around the world. BGI has donated over 130,000 tests since the beginning of the outbreak to regions and countries most in need of testing.
BGI's Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV is the first FDA-approved product manufactured in China. It is also BGI's first FDA-approved medical device.
BGI is bringing its full genomics expertise and resources to the fight against the 2019 novel coronavirus throughout the world. BGI's long history of timely response to public health crisis events dates back to 2003, when the company decoded the genome of the SARS coronavirus and developed the virus detection kit within 96 hours. During the 2014 West African Ebola outbreak, BGI quickly set up a front-line laboratory in Sierra Leone and helped to develop virus detection kits.
More information: www.bgi.com
